dolutegravir, lamivudine DTG (INSTI), 3TC (NRTI)

DHHS recommended initial regimen for most people except those with viral load greater than 500,000 copies/mL, hepatitis B virus (HBV) co-infection, or before results of genotypic resistance or HBV testing
Single-Tablet Regimen

Standard Dose

One tablet once daily, with or without food, for treatment-naïve people who have no known resistance to components of the regimen: dolutegravir and lamivudine.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Dovato is not recommended for people who have severe liver impairment. According to the drug label, Dovato is not recommended for people with decreased kidney function (now down to a creatinine clearance less than 30 mL/min) due to the lamivudine component. This medication combination, however, is often used in reduced renal function below 30 mL/min because of the relatively minimal risk of lamivudine accumulation and side effects. In addition, reduced doses may be obtained by using the individual components of this medication as needed.
  • See the individual drugs contained in this medication: Tivicay and Epivir.
  • See package insert for more complete information on potential side effects and interactions.


ViiV Healthcare;
(877) 844-8872



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments